MCID: RFR004
MIFTS: 31

Refractory Hematologic Cancer

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Refractory Hematologic Cancer

MalaCards integrated aliases for Refractory Hematologic Cancer:

Name: Refractory Hematologic Cancer 12 15
Refractory Hematologic Malignancy 70

Classifications:



External Ids:

Disease Ontology 12 DOID:712
NCIt 50 C27357
UMLS 70 C1335724

Summaries for Refractory Hematologic Cancer

Disease Ontology : 12 A hematologic cancer that is located in the blood or bone marrow that doesn't respond to treatment.

MalaCards based summary : Refractory Hematologic Cancer, also known as refractory hematologic malignancy, is related to refractory hairy cell leukemia and eye lymphoma. An important gene associated with Refractory Hematologic Cancer is CD22 (CD22 Molecule), and among its related pathways/superpathways are NF-kappaB Signaling and Oxytocin signaling pathway. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotype is Reduced mammosphere formation.

Related Diseases for Refractory Hematologic Cancer

Diseases related to Refractory Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 refractory hairy cell leukemia 29.6 MSLN HLA-DRB1 FURIN EEF2 DAP CD22
2 eye lymphoma 10.2 CD22 CD19
3 relapsed/refractory diffuse large b-cell lymphoma 10.2 CD22 CD19
4 alpha chain disease 10.2 CD22 CD19
5 adult lymphoma 10.2 CD22 CD19
6 spleen cancer 10.2 CD22 CD19
7 capillary leak syndrome 10.1 CD22 CD19
8 splenic disease 10.1 CD22 CD19
9 mental retardation, autosomal dominant 10 10.1 CD38 CD22
10 soft palate cancer 10.1 TNFRSF4 CD22
11 mental retardation, autosomal dominant 33 10.1 CD38 CD22
12 b cell prolymphocytic leukemia 10.1 CD38 CD19
13 prolymphocytic leukemia 10.1 CD38 CD19
14 mental retardation, autosomal dominant 36 10.1 CD38 CD19
15 invasive malignant thymoma 10.1 CD38 CD19
16 adult acute lymphocytic leukemia 10.0 CD22 CD19
17 schuurs-hoeijmakers syndrome 10.0 CD38 CD19
18 mulchandani-bhoj-conlin syndrome 10.0 CD38 CD19
19 richter's syndrome 10.0 CD38 CD19
20 multicentric castleman disease 10.0 CD38 CD19
21 plasma protein metabolism disease 10.0 CD38 CD19
22 monoclonal gammopathy of uncertain significance 9.9 CD38 CD19
23 cll/sll 9.9 CD38 CD22 CD19
24 lymphoplasmacytic lymphoma 9.9 CD38 CD22 CD19
25 mature b-cell neoplasm 9.9 CD38 CD22 CD19
26 hypersensitivity reaction type iv disease 9.9 HLA-DRB1 CD19
27 waldenstroem's macroglobulinemia 9.9 CD38 CD19
28 blood protein disease 9.9 CD38 CD19
29 nodular goiter 9.9 TNFRSF4 BRAF
30 marginal zone b-cell lymphoma 9.8 CD22 CD19
31 hairy cell leukemia 9.8 CD38 CD22 BRAF
32 common variable immunodeficiency 9.8 HLA-DRB1 CD38 CD19
33 lymphoma, non-hodgkin, familial 9.6 CD38 CD22 CD19 BRAF
34 leukemia, chronic lymphocytic 9.5 CD38 CD22 CD19 BRAF
35 systemic lupus erythematosus 9.3 TNFRSF4 HLA-DRB1 CD38 CD22 CD19

Graphical network of the top 20 diseases related to Refractory Hematologic Cancer:



Diseases related to Refractory Hematologic Cancer

Symptoms & Phenotypes for Refractory Hematologic Cancer

GenomeRNAi Phenotypes related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 BRAF CD22 DAP EEF2 TNFRSF4

Drugs & Therapeutics for Refractory Hematologic Cancer

Drugs for Refractory Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
3
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
4
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
5
Mycophenolic acid Approved Phase 2 24280-93-1 446541
6
Thiotepa Approved, Investigational Phase 1, Phase 2 52-24-4 5453
7
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
8
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
9
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
10
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
11
Etoposide Approved Phase 2 33419-42-0 36462
12
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
13
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
14
Zanubrutinib Approved, Investigational Phase 1, Phase 2 1691249-45-2
15
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
16
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
17
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
18
Lomustine Approved, Investigational Phase 1, Phase 2 13010-47-4 3950
19
Daratumumab Approved Phase 1, Phase 2 945721-28-8
20
nivolumab Approved Phase 1, Phase 2 946414-94-4
21
Pomalidomide Approved Phase 1, Phase 2 19171-19-8
22
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
23
Idelalisib Approved Phase 2 870281-82-6
24
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
25
Molgramostim Investigational Phase 2 99283-10-0
26 Antifungal Agents Phase 2
27 Muromonab-CD3 Phase 2
28 Analgesics Phase 2
29 Etoposide phosphate Phase 2
30 Alkylating Agents Phase 1, Phase 2
31 Antibiotics, Antitubercular Phase 1, Phase 2
32 Anti-Bacterial Agents Phase 1, Phase 2
33 Hemostatics Phase 1, Phase 2
34 Tubulin Modulators Phase 1, Phase 2
35 topoisomerase I inhibitors Phase 1, Phase 2
36 Antimitotic Agents Phase 1, Phase 2
37
Liposomal doxorubicin Phase 1, Phase 2 31703
38 Antineoplastic Agents, Immunological Phase 1, Phase 2
39 Pharmaceutical Solutions Phase 1, Phase 2
40 Angiogenesis Inhibitors Phase 1, Phase 2
41
Ciclopirox Approved, Investigational Phase 1 29342-05-0 2749
42
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
43
Panobinostat Approved, Investigational Phase 1 404950-80-7 6918837
44
Vincristine Approved, Investigational Phase 1 2068-78-2, 57-22-7 5978
45
rituximab Approved Phase 1 174722-31-7 10201696
46
Zoledronic Acid Approved Phase 1 118072-93-8 68740
47
Venetoclax Approved, Investigational Phase 1 1257044-40-8 49846579
48
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
49
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 High-Dose Chemoradiotherapy With Stem Cell Allogeneic Cellular Rescue in Patients With Relapsed or Refractory Hematologic Malignancy - A Phase I/II Study Completed NCT00004907 Phase 1, Phase 2 busulfan;cyclophosphamide;etoposide
2 Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
3 A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT00086125 Phase 2 ridaforolimus
4 A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies Completed NCT00047021 Phase 2 cytarabine;mitoxantrone hydrochloride
5 Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies Completed NCT00202917 Phase 1, Phase 2 Fludarabine;Thiotepa;Melphalan;OKT-3
6 A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy Completed NCT00558675 Phase 1, Phase 2
7 Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies Completed NCT01025778 Phase 2 Clofarabine for remission induction;Etoposide for remission induction;Cyclophosphamide for remission induction;Clofarabine in conditioning before transplantation;Thiotepa in conditioning before transplantation;Melfalan in conditioning before transplantation
8 A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies Completed NCT01943851 Phase 2 GSK525762
9 Cladribine With Intermediate Cytarabine, G-CSF and VP16 Sequential With Fludarabine and Busulifan as Condoning Regimen for Refractory Acute Leukemia Recruiting NCT03882203 Phase 2 CLAGE-FluBu
10 An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies Recruiting NCT03648372 Phase 1, Phase 2 TAK-981
11 A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting NCT03162536 Phase 1, Phase 2 ARQ 531;ARQ 531
12 Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors Recruiting NCT03678883 Phase 1, Phase 2 9-ING-41;Gemcitabine - 21 day cycle;Doxorubicin.;Lomustine;Carboplatin.;Nab paclitaxel.;Paclitaxel.;Gemcitabine - 28 day cycle;Irinotecan
13 Clinical Trial for the Safety and Efficacy of Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions Recruiting NCT04790747 Phase 1, Phase 2 CAR-T cells
14 Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies Active, not recruiting NCT01592370 Phase 1, Phase 2 Pomalidomide;Dexamethasone
15 A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Refractory Hematologic Malignancies Terminated NCT00838890 Phase 1, Phase 2 Cdc7-inhibitor (BMS-863233);Cdc7-inhibitor (BMS-863233)
16 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated NCT01799889 Phase 2 Entospletinib MM;Entospletinib SDD
17 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated NCT01796470 Phase 2 Entospletinib;Idelalisib
18 A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning Terminated NCT00861965 Phase 1, Phase 2
19 A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies Terminated NCT00522990 Phase 1, Phase 2 AT9283
20 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Withdrawn NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
21 Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, in Patients With Progressive and/or Refractory Hematologic Malignancies Withdrawn NCT02223312 Phase 1, Phase 2
22 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Unknown status NCT03838926 Phase 1 Trichostatin A
23 A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies Completed NCT00904787 Phase 1 ENMD-2076
24 Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Completed NCT00990587 Phase 1 Ciclopirox Olamine
25 A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT02543879 Phase 1 FT-1101;Azacitidine
26 A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Completed NCT00506402 Phase 1 MKC-1
27 A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies Completed NCT02352558 Phase 1 BBI608;Dexamethasone;Bortezomib;Imatinib;Ibrutinib
28 A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies Completed NCT00047489 Phase 1 ABT-751
29 A Phase I Trial of Myeloablative Conditioning Using Clofarabine and High-Dose Busulfan for Patients With Refractory Hematological Malignancies Undergoing Allogeneic HSCT Completed NCT00477542 Phase 1 clofarabine
30 Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies Completed NCT02240719 Phase 1 everolimus;bendamustine hydrochloride
31 A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Completed NCT03106428 Phase 1 MEDI7247
32 A Phase I Study of XK469R (NSC 698215) in Patients With Refractory Hematologic Malignancies Completed NCT00095797 Phase 1 R(+)XK469
33 An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors Completed NCT01844869 Phase 1 omacetaxine mepesuccinate
34 A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01767766 Phase 1 TGR-1202
35 A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
36 A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies Completed NCT00595686 Phase 1 SNX-5422
37 A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1) Completed NCT01344876 Phase 1 OPB-51602
38 An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma Completed NCT00900614 Phase 1 APR-246
39 A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies Completed NCT02160951 Phase 1 LGH447
40 A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed NCT01321346 Phase 1 Panobinostat;Cytarabine;Panobinostat
41 Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies Completed NCT00824135 Phase 1 Clofarabine;Thiotepa;Melphalan;Mycophenolate mofetil;Rituximab
42 A Phase I Trial Using Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies Completed NCT00718757 Phase 1 Dexamethasone;Irinotecan;Vincristine
43 A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies Completed NCT00710528 Phase 1 CAL-101
44 A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT02017613 Phase 1 RP6530
45 A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies Completed NCT01943682 Phase 1 CPX-351
46 Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
47 A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies Completed NCT01635712 Phase 1 SNX-5422
48 A Dose Escalation Phase I Study of Asparec®(mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies Completed NCT01551524 Phase 1
49 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies Completed NCT02071888 Phase 1 CB-839;CB-839 and low dose dexamethasone;CB-839, pomalidomide, and low dose dexamethasone
50 A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets Recruiting NCT04412577 Phase 1 TQB3473

Search NIH Clinical Center for Refractory Hematologic Cancer

Genetic Tests for Refractory Hematologic Cancer

Anatomical Context for Refractory Hematologic Cancer

MalaCards organs/tissues related to Refractory Hematologic Cancer:

40
Bone Marrow, T Cells, Bone, Liver, Prostate, Myeloid

Publications for Refractory Hematologic Cancer

Articles related to Refractory Hematologic Cancer:

(show all 15)
# Title Authors PMID Year
1
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. 61
32193289 2020
2
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. 61
31958813 2020
3
CAR T cell therapy: A new era for cancer treatment (Review). 61
31578576 2019
4
Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. 61
29337223 2018
5
Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies. 61
27416327 2016
6
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. 61
27269947 2016
7
[Myelodysplastic syndromes (MDS)]. 61
25016808 2014
8
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. 61
23426943 2013
9
Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review. 61
15291347 2004
10
Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. 61
15017608 2004
11
Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. 61
12091334 2002
12
Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy. 61
12007954 2002
13
Application of Resistance Reversal Agents in Hematologic Malignancies; Malignancy; Current Clinical Practice. 61
11399634 2001
14
Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies. 61
27420926 2000
15
L-asparaginase and PEG asparaginase--past, present, and future. 61
8481665 1993

Variations for Refractory Hematologic Cancer

Expression for Refractory Hematologic Cancer

Search GEO for disease gene expression data for Refractory Hematologic Cancer.

Pathways for Refractory Hematologic Cancer

GO Terms for Refractory Hematologic Cancer

Cellular components related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.73 HLA-DRB1 FURIN EEF2 CD38 CD22 CD19
2 plasma membrane GO:0005886 9.61 TNFRSF4 MSLN HLA-DRB1 FURIN EEF2 CD38
3 membrane raft GO:0045121 9.5 FURIN EEF2 CD19
4 external side of plasma membrane GO:0009897 9.46 TNFRSF4 HLA-DRB1 CD22 CD19
5 cell surface GO:0009986 9.1 TNFRSF4 MSLN HLA-DRB1 FURIN CD38 CD22

Biological processes related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of B cell proliferation GO:0030890 8.62 TNFRSF4 CD38

Molecular functions related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CD4 receptor binding GO:0042609 8.62 HLA-DRB1 CD22

Sources for Refractory Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....